Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
RenJi Hospital
Modality
radiopharmaceutical
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06851663CT.gov Trop2-targeted immunoPET Imaging of Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [18f]f-resca-rt4 (this asset) | RenJi Hospital | P2/3 | CCC · 50 |
| Indocyanine Green | Istanbul University | P4 | BB |
| Adriamycin | AstraZeneca | P3 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Olaparib | Qilu Pharmaceutical Co., Ltd. | P4 | BB |
| Nivestim | Mayo Clinic | P3 | B |
| Capivasertib | M.D. Anderson Cancer Center | P2 | B |
| Docetaxel | Merck Sharp & Dohme LLC | P3 | B |
| Ceralasertib | National Cancer Institute (NCI) | P2 | B |
+42 more in the Endometrial Carcinoma cohort
Other indications for [18f]f-resca-rt4
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urothelial Carcinoma | — | P2/3 | B · 57 |
| Nasopharyngeal Carcinoma | — | P2/3 | B · 57 |
| Carcinoma | — | P2/3 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [18f]f-resca-rt4 in Endometrial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/18ff-resca-rt4-endometrial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →